1 active not recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Recurrent Fallopian Tube Clear Cell Adenocarcinoma: new trials by email Literature Review of Recurrent Fallopian Tube Clear Cell Adenocarcinoma trials Research Report on Recurrent Fallopian Tube Clear Cell Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, Bevacizumab, Computed Tomography - Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 444 | 2017-06-23 | 2026-10-26 |
Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1)
Adnexal Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Fallopian Tube Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Genital Diseases (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Gonadal Disorders (1) · Neoplasms (1) · Neoplasms by Site (1) · Ovarian Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
Bevacizumab (1) · Disulfides (1) · Doxorubicin (1) · Immunoglobulin G (1) · atezolizumab (1) · liposomal doxorubicin (1)
National Cancer Institute (NCI) (1)
Puerto Rico (1) · United States (1)
U10CA180868 (1)